Asia Spotlight: China's Top Drug Distributors Are Soaring
On the second Monday of each month, "The Pink Sheet" provides exclusive news and commentary on the Asia biopharma market from the editors of its affiliated online publication, PharmAsia News. Register at http://pharmasianews.elsevierbi.com/PAN_Trial_LP.html for a free trial.
You may also be interested in...
WuXi Celebrates First $100 Million Quarter; Sinovac Reports 50% Revenue Increase; SciClone Not Worried About Zydaxin Cuts: China Earnings Round Up (Part 1)
China's major players rack up double-digit growth in the second quarter, with WuXi PharmaTech celebrating its first $100 million quarter and Sinovac seeing a 50% increase in revenues. On the heels of the NovaMed acquisition, SciClone Pharmaceuticals Inc. is preparing to enter more markets in China and anticipates price cuts for its flagship product Zadaxin. In a recurring feature, PharmAsia News combs through earnings calls to bring readers the highlights in the critical emerging markets.
With Latest Round Of Cuts, China Continues March To Narrow Gap Between Big Pharma And Local Generics
SHANGHAI - As expected, China's powerful National Development and Reform Commission announced Aug. 5 a new round of price cuts, this time targeting hormone and endocrinology drugs and central nervous system drugs, with an average cut of roughly 14%, according to analysts
HONG KONG - Meetings with government officials involved with the tender process in China's Anhui province suggest that the impact of price cuts for essential drugs has been greater than expected, Morgan Stanley analysts say in a June 6 research report